


The WIN Consortium in Precision Oncology

www.winconsortium.org









WIN was formed on the premise that Consortium members can accomplish together what no single institution or group of patients can do alone.

WIN was founded in France as a non-profit by **Dr. John Mendelsohn, Past President MD Anderson Cancer Center, Houston, Chairman of WIN until his death and Prof. Thomas Tursz, General Director Gustave Roussy, France.**

WIN BOLD MISSION: Significantly improve survival of cancer patients across the world through international collaboration.

STRATEGY: Perform proof-of-concept cancer clinical trials designed to explore novel strategies and tools to increase efficacy of Precision Oncology and improve early diagnosis

WIN History

John Mendelsohn , Past President MD Anderson Cancer Center, Houston, USA	Chair, WIN 2010 - 2018	
Thomas Tursz , Past General Director Gustave Roussy, Villejuif, France	Vice-Chair, WIN 2010 - 2012, 2016 - 2018	
Alexander Eggermont , Past General Director Gustave Roussy, Villejuif, France	Vice-Chair, WIN 2012 - 2016	
Josep Tabernero , Head Vall d'Hebron Institute of Oncology, Barcelona, Spain	Vice-Chair, WIN 2018 - 2023	
Richard L.Schilsky , Past President, former Executive VP and Chief Medical Officer, ASCO, USA	Chair, WIN 2018 - 2023	
Wafik El-Deiry , Director, Legorreta Cancer Center, Associate Dean, Oncologic Sciences, Warren Alpert Medical School, Brown University, Providence, USA	Chair, WIN 2024 -	

Publications

WINTHER trial results

J. Rodon et al., Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. **Nature Medicine** volume 25, pages 751-758 (2019)

Simplified interventional mapping system (SIMS)

Lazar V., et al. A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer. **Oncotarget**. (2015); 6: 14139-14152

Solomon B, et al. A WIN Consortium phase I study exploring avelumab, palbociclib, and axitinib in advanced non-small cell lung cancer. **Cancer Med** . (2022) ;00:1-11

Digital Display Precision Predictor (DDPP)





Lazar, V., et al., Digital Display Precision Predictor: the prototype of a global biomarker model to guide treatments with targeted therapy and predict progression-free survival. (2021) **npj Precis. Onc.** 5, 33.

Lazar, V., et al., Transcriptomics in tumor and normal lung tissues identify patients with early stage NSCLC with high risk of post-surgery recurrence who may benefit from adjuvant therapies **JCO Precision Oncology** no. 6 (2022) e2200072. Published online

Lazar, V., et al., Comorbidity between lung cancer and COVID-19 pneumonia: role of immunoregulatory gene transcripts in high ACE2-expressing normal lung. **Therapeutic Advances in Medical Oncology** (2022), Vol. 14: 1-15

Lazar, V., et al., A transcriptomics approach to expand therapeutic options and optimize clinical trials in oncology. **Ther Adv Med Oncol** (2023), Vol. 15: 1-15

WIN New Leadership

Wafik El-Deiry , Director, Legorreta Cancer Center Associate Dean, Oncologic Sciences Warren Alpert Medical School, Brown University	Chair, WIN	
Razelle Kurzrock , Associate Director, Clinical Research, MCW Cancer Center and Linda T. and John A. Mellows Endowed Chair of Precision Oncology	CMO & Equal Opportunity and Diversity Officer, WIN	
Yves A. Lussier , Professor and Chair, Dpt Biomedical Informatics, The University of Utah School of Medicine, USA	Chair SAB, WIN	
Richard L.Schilsky , Past President, former Executive Vice-President and Chief Medical Officer, ASCO, USA	Chair emeritus, WIN	

WIN 27 Members

WIN Consortium Members	
Academic Institutions in Americas 	Industries 
Academic Institutions in Asia 	Non-Profit Organizations 
Academic Institutions in Europe 	<p>World-class academic medical centers (23), industries (1), research and patient advocate organizations (3).</p> <p>27 members in 18 countries and 5 continents Access to > 5,000,000 patients www.winconsortium.org www.winsymposium.org</p>

WIN Value Proposition

- ❑ Access to:
 - Global thought leaders in Precision Oncology
 - Platform of leading cancer centers across the world
- ❑ Expertise in genomics and transcriptomics
- ❑ Experience and success with:
 - Complex biomarker-directed clinical trials (WINTHER trial)
 - Obtaining high quality tissues and bloods for comprehensive genomics and transcriptomics
 - Managing international multi-site trials
 - International Molecular Tumor Board
- ❑ Ability to partner with companies and philanthropic organizations or individuals to perform Precision Oncology studies to:
 - Better identify treatment options for patients including optimal dosing of novel combination therapies
 - Understand mechanisms of resistance to cancer therapy
 - Improve patients' treatment follow-up and early diagnosis non-invasively
 - Accelerate drug development through better patient selection

A Vision for WIN's Future

- ❑ Expand the WIN membership with additional:
 - World-class cancer centers in US and across the globe
 - Diagnostics, AI, pharma companies, patient-advocacy organizations, non-profits
- ❑ Leveraging WIN's platform for global academic members to:
 - Partner with companies for compelling Precision Oncology and Early Diagnosis studies across the globe
 - Build upon transcriptomics' experience acquired in international clinical trials like WINTHER and others that have so much potential
 - Accelerate trial results delivery and simplify management of multi-site international trials
- ❑ Leverage WIN IP (algorithm for patient's treatment matching and patient stratification)
- ❑ New initiatives such as international Molecular Tumor Board
- ❑ Catalyze Think Tanks to pursue the most exciting directions, involve WIN's exceptional SAB; Innovation and Collaboration globally to ensure continued success
- ❑ Strengthen relationships with professional societies (ACS, ASCO, AACI, AACR, etc.)



WIN's 13th symposium by co-chairs Prof. W El-Deiry and Dr. R Kurzrock in a series of remarkable ASCO and ESO endorsed symposia. 1-2 March 2024 in Rosewood Hotel, Abu Dhabi, UAE

Nobel Laureate Jim Allison (MDACC)
Padmanee Sharma (MDACC)
Vivek Subbiah (Sarah Cannon Research Institute)
Sendurai Mani (Brown University)

- Representation at international general assembly (right to vote on all decisions)
- Access to governance positions (2-year mandates)
- Ability to participate in WIN-managed studies
- Ability to propose studies to be performed in WIN member institutions, but no obligation
- Each project is subject to contract negotiated in good faith. Usual IP rules apply
- Each project needs a separate funding mechanism. All participants in studies required to participate in the effort
- Visibility on website, symposia

Annual Membership Dues

Academics: From 5,000 to 50,000 € depending on research budget

Industries: Pharma 250,000 €; Technology partners 100,000 €

Organizations we have collaborated with

